OJPed  Vol.2 No.4 , December 2012
Case of purine nucleoside phosphorylase deficiency presented with hematuria
Abstract: Purine Nucleoside Phosphorylase (PNP) deficiency is a rare autosomal recessive metabolic disorder. In PNP-deficiency disorder, the deficient enzyme leads to accumulation of toxic metabolites, especially in lymphocytes and the metabolites exert toxic effect on T-cell generation. Purine nucleoside phosphorylase deficiency causes decreased numbers of T cells and lymphopenia. The patients suffering from PNP-deficiency may be admitted with recurrent infections, as well as neurological and autoimmune findings. We hereby presented a case admitted with the symptom of hematuria in which we established the diagnosis of PNP-deficiency early on the basis of detection of lymphopenia and low level of uric acid.
Cite this paper: Girit, S. , Genel, F. , Can, D. , Bak, M. and Hershfield, M. (2012) Case of purine nucleoside phosphorylase deficiency presented with hematuria. Open Journal of Pediatrics, 2, 268-271. doi: 10.4236/ojped.2012.24044.

[1]   Walker, P.L., Corrigan, A., Arenas, M., Escuredo, E., Fairbanks, L. and Marinaki, A. (2011) Purine nucleoside phosphorylase deficiency: A mutation update. Nucleosides Nucleotides Nucleic Acids, 30, 1243-1250. doi:10.1080/15257770.2011.630852

[2]   Hershfield, M.S. and Mitchell, B.S. (2001) Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D., Eds., The Metabolic and Molecular Basis of Inherited Disease, McGraw-Hill, New York, 2585-2625.

[3]   Papinazath, T., Min, W., Sujiththa, S., Cohen, A., Ackerley, C., Roifman, C.M. and Grunebaum, E. (2011) Effects of purine nucleoside phosphorylase deficiency on thymocyte development. Journal of Allergy and Clinical Immunology, 128, 854-863. doi:10.1016/j.jaci.2011.07.039

[4]   Micheli, V., Camici, M., Tozzi, M.G., Ipata, P.L., Sestini, S., Bertelli, M. and Pompucci, G. (2011) Neurological disorders of purine and pyrimidine metabolism. Current Topics in Medicinal Chemistry, 11, 923-947. doi:10.2174/156802611795347645

[5]   Cohen,A., Gudas, L.J., Ammann, A.J., Staal, G.E.J. and Martin, D.W. (1978) Deoxyguanosine Triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. The Journal of Clinical Investigation, 61, 1405-1409. doi:10.1172/JCI109058

[6]   Alangari, A., Al-Harbi, A., Al-Ghonaium, A., Santisteban, I. and Hershfield, M. (2009) Purine nucleoside phosphorylase deficiency in two unrelated Saudi patients. Annals of Saudi Medicine, 29, 309-321. doi:10.4103/0256-4947.55320

[7]   Gelfand, E.W., Dosch, H.M., Biggar, W.D. and Fox, I.H. (1978) Partial purine nucleoside phosphorylase deficiency: Studies of Lymphocyte function. The Journal of Clinical Investigation, 61, 1405-1409.

[8]   Notarangelo, L.D. (2009) Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology: American Society of Hematology Education Program Book, 2009, 139-182. doi:10.1182/asheducation-2009.1.139

[9]   Tabarki, B., Yacoub, M., Tlili, K., Trabelsi, A., Dogui, M. and Essoussi, A.S. (2003) Familial spastic paraplegia as the presenting manifestation in patients with purine nucleoside phosphorylase deficiency. Journal of Child Neurology, 18, 140-141. doi:10.1177/08830738030180021001

[10]   Ozkinay, F., Pehlivan, S., Onay, H., van den Berg, P., Vardar, F., Koturoglu, G., Aksu, G., Unal, D., Tekgul, H., Can, S. and Ozkinay, C. (2007) Purine nucleoside phosphorylase deficiency in a patient with spastic paraplegia and recurrent infections. Journal of Child Neurology, 22, 741-743. doi:10.1177/0883073807302617

[11]   Parvaneh, N., Ashrafi, M.R., Yeganeh, M., Pouladi, N., Sayarifar, F. and Parvaneh, L. (2007) Progressive multifocal leukoencephalopathy in purine nucleoside phosphorylase deficiency. Brain & Development, 29, 124-130. doi:10.1016/j.braindev.2006.07.008

[12]   Soutar, R.L. and Day, R.E. (1991) Dysequilibrium/ataxic diplegia with immunodeficiency. Archives of Disease in Childhood, 66, 982-983. doi:10.1136/adc.66.8.982

[13]   Classen, C.F., Schulz, A.S., Sigl-Kraetzig, M., Hoffmann, G.F., Simmonds, H.A., Fairbanks, L., Debatin, K.M. and Friedrich, W. (2001) Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. Bone Marrow Transplantation, 28, 93-96. doi:10.1038/sj.bmt.1703100

[14]   Fischer, A., Landais, P., Friedrich, W., Gerritsen, B., Fasth, A., Porta, F., Vellodi, A., Benkerrou, M., Jais, J.P., Cavazzana-Calvo, M., Souillet, G., Bordigoni, P., Morgan, G., Van Dijken, P., Vossen, J., Locatelli. F. and di Bartolomeo, P. (1994) Bone marrow transplantation (BMT) in Europore primary immunodeficiencies other than severe combined immunodeficiency: A report from the European group for BMT and the European group for immunodeficiency. Blood, 183, 149-154.

[15]   Carpenter, P.A., Ziegler, J.B. and Vowels, M.R. (1996) Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation. Bone Marrow Transplantation, 17, 121-125.

[16]   Delicou, S., Kitra-Roussou, V., Peristeri, J., Goussetis, E., Vessalas, G., Rigatou, E., Psychou, F., Salavoura, K. and Grafakos, S. (2007) Successful HLA-identical hematopoietic stem cell transplantation in a patient with purine nucleoside phosphorylase deficiency. Pediatric Transplantation, 11, 799-803. doi:10.1111/j.1399-3046.2007.00772.x

[17]   Hamada, T., Ichida, K., Hosoyamada, M., Mizuta, E., Yanagihara, K., Sonoyama, K., Sugihara, S., Igawa, O., Hosoya, T., Ohtahara, A., Shigamasa, C., Yamamoto, Y., Ninomiya, H. and Hisatome, I. (2008) Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT1) in hypertensive patients. American Journal of Hypertension, 21, 1157-1219. doi:10.1038/ajh.2008.245